Blocking the prostaglandin E2 (PGE2)‐EP1‐Gaq‐Ca2+ signal pathway in glomerular mesangial cells (GMCs) by internalizing prostaglandin E2 receptor 1 (EP1) with GRK2 may be a potential treatment for diabetic nephropathy (DN). Here, GNAQ is linked to diabetic kidney disease.